Replimune (REPL) Cash & Equivalents (2018 - 2026)
Replimune (REPL) posted Cash & Equivalents of $209.0 million for Q1 2026, up 70.01% sequentially from $123.0 million in Q4 2025, and up 88.11% YoY from $111.1 million in Q1 2025.
Replimune (REPL) Cash & Equivalents (2018 - 2026) Analysis & Trends
Replimune has reported Cash & Equivalents for 9 years, with the latest figure at $209.0 million in Q1 2026.
- Quarterly Cash & Equivalents rose 88.11% year-over-year to $209.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $209.0 million (up 88.11% YoY) and the FY2026 annual result came in at $209.0 million, up 88.11% from the prior year.
- Cash & Equivalents climbed to $209.0 million in Q1 2026 per REPL's latest filing, from $123.0 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $209.0 million in Q1 2026 and troughed at $74.5 million in Q1 2024.
- A 5-year average of $121.4 million and a median of $111.1 million in 2025 frame the typical range for Cash & Equivalents.
- The widest YoY moves for Cash & Equivalents: up 95.19% in 2023, down 52.74% in 2023.
- Over 5 years, Cash & Equivalents stood at $206.7 million in 2022, then slumped by 52.74% to $97.7 million in 2023, then jumped by 76.35% to $172.2 million in 2024, then retreated by 28.62% to $123.0 million in 2025, then soared by 70.01% to $209.0 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $209.0 million, $123.0 million, and $102.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | 209.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 209.02 Mn |
| Dec 31, 2025 | 122.95 Mn |
| Sep 30, 2025 | 102.30 Mn |
| Jun 30, 2025 | 97.37 Mn |
| Mar 31, 2025 | 111.12 Mn |
| Dec 31, 2024 | 172.25 Mn |
| Sep 30, 2024 | 113.49 Mn |
| Jun 30, 2024 | 151.66 Mn |
| Mar 31, 2024 | 74.46 Mn |
| Dec 31, 2023 | 97.67 Mn |
| Sep 30, 2023 | 76.00 Mn |
| Jun 30, 2023 | 106.48 Mn |
| Mar 31, 2023 | 146.59 Mn |
| Dec 31, 2022 | 206.67 Mn |
| Sep 30, 2022 | 88.93 Mn |
| Jun 30, 2022 | 112.25 Mn |
| Mar 31, 2022 | 75.10 Mn |
| Dec 31, 2021 | 132.28 Mn |
| Sep 30, 2021 | 159.97 Mn |
| Jun 30, 2021 | 192.53 Mn |